Harrow secures exclusive U.S. rights to two ophthalmology biosimilars from Samsung Bioepis

HARROW, INC.

Gains exclusive U.S. commercial rights to BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), FDA-approved biosimilars of Lucentis and Eylea.
Consideration includes one-time upfront payment, net-sales milestone payments, and a share of U.S. net sales (amounts not disclosed).
Transition of commercial rights from Biogen to Samsung expected by end of 2025; Harrow will then assume full commercialization.
U.S. retinal disease treatment market valued at ~$9B; products target Wet AMD, Macular Edema, DME, and Diabetic Retinopathy.
CEO Mark Baum calls the acquisition transformational, reinforcing Harrow's commitment to affordable alternatives in eyecare.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.